References
- Arnold DM, Kelton JG. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007; 44(suppl 5)s12–s23
- Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008
- Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect. Blood 1991; 77: 1884–1893
- Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109: 1401–1407
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009; 113(11)2386–2393
- Scaradavou A, Woo B, Woloski BMR, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB. Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood 1997; 89: 2689–2700
- Aledort LM, Salama A, Kovaleva L, et al. Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpura. Hematology 2007; 12: 289–295
- Newman GC, Novoa MV, Fodero EM, et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Hematol 2001; 112: 1076–1078
- Rodeghiero F, Schiavotto C, Castaman G, Vespignani M, Ruggeri M, Dini E. A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. Haematologica 1992; 77: 248–252
- Cooper N, Woloski BM, Fodero EM, Novoa M, Leber M, Beer JH, Bussel JB. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. Blood 2002; 99: 1922–1927
- Schwartz J, Spitalnik S, Grima KM. Severe hemolysis following administration of Rho(D) immune globulin in an ITP patient associated with anti-C. Blood 2006; 107: 2585
- Sandler SG, Mallory D, Trimble J, Nance ST. Intravenous anti-D treatment for immune thrombocytopenic purpura. Blood 1998; 91: 2624–2625
- Kjaersgaard M, Aslam R, Kim M, Speck ER, Freedman J, Stewart DIH, Wiersma EJ, Semple JW. Epitope specificity and isotype of monoclonal anti-D antibodies dictate their ability to inhibit phagocytosis of opsonized platelets. Blood 2007; 110: 1359–1361
- Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120(4):574-596.
- Ramadan KM, El-Agnaf M. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. Clin Lab Haematol 2005; 27(4)267–269
- Kayyali HR, Abdelmoity AT, Morriss MC, Graf WD. Cerebral venous thrombosis after immune thrombocytopenic purpura and anti-D immune globulin therapy. J Child Neurol 2008; 23(3)325–330
- Berger-Achituv S, Ellis MH, Curtis BR, Wolach B. Transfusion-related acute lung injury following intravenous anti-D administration in an adolescent. Am J Hematol 2008; 83(8)676–678